Work

CO68 Simulated mOS of Gemcitabine+Carboplatin ± Maintenance Avelumab Therapy or Enfortumab Vedotin + Pembrolizumab in First-Line Treatment of LA/mUC in Patients Ineligible for Cisplatin Using Disease Modeling

Year: 2023

Type: conference-abstract

Source: Value in Health

DOI: 10.1016/j.jval.2023.03.142

Authors: M.D. Galsky, G.P. Sonpavde, B. Bloudek, M. Farrar, Z. Hepp, J. Timmons, T. Powles

Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, AdventHealth Orlando, AdventHealth, Seagen (United States), Queen Mary University of London

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4380150833

Cites:

Cited by:

Related to: 10